Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01835665 · ClinicalTrials.gov registry record · Phase 1
Dose Finding Study of Nimodipine for the Treatment of Progranulin Insufficiency From GRN Gene Mutations
A Phase 1 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT01835665: Completed Phase 1 study, sponsored by University of California, San Francisco.
NCT01835665 is a Phase 1 study that has completed, run by University of California, San Francisco. The registered enrollment target is 8 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01835665, a Phase 1 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the maximum tolerated dose of nimodipine as well as the safety and tolerability of oral nimodipine in progranulin mutation carriers in preparation for longer term efficacy studies in patients with frontotemporal dementia due to progranulin gene mutations.
Primary Outcome
Nimodipine dose will be increased weekly for four weeks then maintained for 4 weeks at highest tolerated dose, followed by a 1-week taper.
Interventions
- DRUG Nimodipine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2013-03 |
| Est. Completion | 2016-05 |
| Phase | Phase 1 |
What the finished NCT01835665 record still lists
NCT01835665 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 1 intervention - of which Nimodipine is the first listed.
NCT01835665 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01835665 about?
NCT01835665 is a clinical study titled "Dose Finding Study of Nimodipine for the Treatment of Progranulin Insufficiency From GRN Gene Mutations". The purpose of this study is to determine the maximum tolerated dose of nimodipine as well as the safety and tolerability of oral nimodipine in progranulin mutation carriers in preparation for longer term efficacy studies in patients with frontotemporal dementia due to progranulin gene mutations.
What is the current status of trial NCT01835665?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2013-03. Estimated completion is 2016-05.
What interventions are being tested in trial NCT01835665?
The interventions under investigation include: Nimodipine (DRUG).
Who is sponsoring clinical trial NCT01835665?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01835665's enrollment target sits among peer trials
8 1959th of 2000 higher than 29 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia